Prioritization of Generic Drug Review (Reply)

In this exchange, FDA officials describe their efforts to expedite review of first-generic and sole-source drug applications, while the authors argue that the FDA should go further by also prioritizing applications for drugs with three or fewer manufacturers and for generics of drugs that have experienced dramatic price increases, They also call for greater transparency around pending applications, failed applications, and reasons for non-approval.